Rivaroxaban Safely Cuts VTE Risk After COVID-19 Hospitalization Rivaroxaban Safely Cuts VTE Risk After COVID-19 Hospitalization

A randomized, open-label trial showed improved clinical outcomes from a low dose of direct oral anticoagulant in patients at high risk for venous thromboembolism and low risk for bleeding.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news